Pulmovant

Roivant Sciences subsidiary developing an inhaled sGC activator in-licensed from Bayer

Subsidiary of Roivant Sciences Ltd. (ROIV) · United States

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Soluble guanylate cyclaseSmall molecule
Pulmonary Hypertension Associated with Interstitial Lung Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
MosliciguatPhase 2Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Est. primary completion 2026-12 · NCT07333183 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
MosliciguatPhase 3Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Est. primary completion 2029-01-28 · NCT07816185 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultMosliciguatPhase 2 PHocus of inhaled mosliciguat in PH-ILD met its primary endpoint
Roivant Sciences Ltd. · Source ↗
10 September 2024Topline resultMosliciguatPhase 1b ATMOS proof-of-concept results for inhaled mosliciguat

Financial reports

No financial reports recorded.